Fidelity Investments
CSTL icon

Fidelity Investments’s Castle Biosciences CSTL Stock Holding History

Fidelity Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.85M Buy
108,390
+52,519
+94% +$1.58M ﹤0.01% 2546
2026
Q2 		$1.33M Buy
55,871
+5,459
+11% +$122K ﹤0.01% 2897
2026
Q1 		$1.24M Buy
50,412
+8,126
+19% +$266K ﹤0.01% 2799
2025
Q4 		$1.64M Buy
42,286
+13,744
+48% +$443K ﹤0.01% 2678
2025
Q3 		$650K Buy
28,542
+4,542
+19% +$92.3K ﹤0.01% 2944
2025
Q2 		$490K Buy
24,000
+22,844
+1,976% +$423K ﹤0.01% 2965
2025
Q1 		$23.1K Buy
1,156
+75
+7% +$1.86K ﹤0.01% 4172
2024
Q4 		$28.8K Buy
1,081
+63
+6% +$1.92K ﹤0.01% 4078
2024
Q3 		$29K Sell
1,018
-202
-17% -$5.14K ﹤0.01% 4016
2024
Q2 		$26.6K Buy
1,220
+348
+40% +$7.76K ﹤0.01% 3939
2024
Q1 		$19.3K Sell
872
-73
-8% -$1.59K ﹤0.01% 4032
2023
Q4 		$20.4K Sell
945
-65
-6% -$1.14K ﹤0.01% 3938
2023
Q3 		$17.1K Buy
1,010
+349
+53% +$6.1K ﹤0.01% 3888
2023
Q2 		$9.07K Sell
661
-52
-7% -$1.05K ﹤0.01% 4179
2023
Q1 		$16.2K Sell
713
-61
-8% -$1.49K ﹤0.01% 3932
2022
Q4 		$18.2K Sell
774
-7
-0.9% -$162 ﹤0.01% 3811
2022
Q3 		$20.4K Buy
781
+224
+40% +$6.28K ﹤0.01% 3847
2022
Q2 		$12.2K Buy
557
+106
+24% +$2.46K ﹤0.01% 4050
2022
Q1 		$20.2K Buy
+451
New +$18.6K ﹤0.01% 4013
2021
Q4 		– Sell
-2
Closed – – 4411
2021
Q3 		$0 Sell
2
-2
-50% -$141 ﹤0.01% 4431
2021
Q2 		$0 Sell
4
-335,241
-100% -$22.1M ﹤0.01% 4329
2021
Q1 		$23M Sell
335,245
-247,706
-42% -$18.6M ﹤0.01% 1745
2020
Q4 		$39.1M Buy
582,951
+167,027
+40% +$9.05M ﹤0.01% 1421
2020
Q3 		$21.4M Buy
415,924
+112,456
+37% +$5M ﹤0.01% 1533
2020
Q2 		$11.4M Buy
+303,468
New +$10.4M ﹤0.01% 1767

Other funds holding CSTL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Fidelity Investments's CSTL Position: Q3 2026 in Review

Fidelity Investments increased its Castle Biosciences (CSTL) stake by 94% in Q3 2026, buying an estimated $1.58M and bringing the position to 108,390 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Fidelity Investments first reported a position in CSTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $39.1M in Q4 2020. 100 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Fidelity Investments held 108,390 shares of Castle Biosciences worth $3.85M as of Q3 2026.
  • Fidelity Investments bought 52,519 Castle Biosciences shares in Q3 2026, an estimated $1.58M.
  • Castle Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #2546 holding.
  • Fidelity Investments first reported a position in Castle Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Fidelity Investments's Castle Biosciences position peaked at $39.1M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.